Identification
of core genes shared by endometrial cancer and ovarian cancer using an integrated approach

Ke, Yu-Min; Zhuang, X Y; You, Liuxia

doi:10.14715/cmb/2022.68.9.22

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and Calcium (Ca2+) is a crucial second messenger in the cell and is involved in a variety of biological processes [6]. To obtain the proper Ca2+ signal, the Ca2+ concentration in the ER must be maintained in a stable state, and ER dysfunction Numerous human cancers, including ovarian carcinoma, and Ca2+ homeostasis are related [7]. The most notable ovarian cancer pathogenesis is Ca2+ transfer between the endoplasmic reticulum and mitochondria, which starts the Krebs cycle and enhances ATP production and biosynthesis while also promoting the spread of the disease [7].…”

Section: Introductionmentioning

confidence: 99%

“…To obtain the proper Ca2+ signal, the Ca2+ concentration in the ER must be maintained in a stable state, and ER dysfunction Numerous human cancers, including ovarian carcinoma, and Ca2+ homeostasis are related [7]. The most notable ovarian cancer pathogenesis is Ca2+ transfer between the endoplasmic reticulum and mitochondria, which starts the Krebs cycle and enhances ATP production and biosynthesis while also promoting the spread of the disease [7]. Because ER-mitochondrial Ca2+ signaling causes cisplatin-triggered cell death, alterations in Ca2+ homeostasis within ER and mitochondria play a key role in ovarian cancer chemoresistance, including cisplatin resistance [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

TMCO1 regulates cell proliferation, metastasis and EMT signaling through CALR, promoting ovarian cancer progression and cisplatin resistance

Guangyu Sun,

Shan Gong,

Suwei Lan

et al. 2024

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study aimed to explore the involvement of Transmembrane and coiled-coil domains 1 (TMCO1) in ovarian cancer progression and its regulatory mechanisms in cisplatin resistance. Using the GEPIA database, we analyzed TMCO1 expression in ovarian cancer and normal tissues. In a cohort of 99 ovarian cancer patients, immunohistochemistry and immunofluorescence were employed to assess TMCO1 expression in tumor and adjacent tissues, correlating findings with clinical and pathological characteristics. TMCO1 overexpression and knockout cell models were constructed, and their impact on non-cisplatin-resistant (SK-OV-3) and cisplatinresistant (SK-OV-3-CDDP) ovarian cancer cells was investigated through cloning, wound healing, Fluo 4, and Transwell experiments. Knocking down CALR and VDAC1 was performed to examine their effects on TMCO1, cell proliferation, and malignant markers. Subcutaneous tumor models in nude mice elucidated the in vivo role of TMCO1 in tumor growth. Expression levels of CALR, VDAC1, angiogenesis indicators (CD34), and epithelial-mesenchymal transition (EMT) markers were evaluated. TMCO1 expression in ovarian cancer tissue significantly differed from normal tissue, correlating with survival rates. TMCO1 overexpression was associated with lymph node metastases, late FIGO stage, and larger tumors. TMCO1 promoted proliferation, calcium ion elevation, cytoskeletal remodeling, and metastasis in SK-OV-3 and SK-OV-3-CDDP cells, upregulating VDAC1, CALR, Vimentin, N-cadherin, β-catenin, and downregulating E-cadherin. Silencing TMCO1 inhibited cell growth, proliferation, and angiogenesis in vivo, suppressing the expression of CALR, VDAC1, Vimentin, N-cadherin, and β-catenin. Overall, this study highlighted TMCO1 as a crucial regulator in ovarian cancer progression, influencing VDAC1 through CALR and impacting diverse cellular processes, offering potential as a targeted therapeutic strategy for ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

TMCO1 regulates cell proliferation, metastasis and EMT signaling through CALR, promoting ovarian cancer progression and cisplatin resistance

Guangyu Sun,

Shan Gong,

Suwei Lan

et al. 2024

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

show abstract

“…Paclitaxelcarboplatin (PC) is the current gold-standard chemotherapy for patients with advanced and recurrent endometrial cancer [1]. Uterine serous carcinoma (USC), a rare pathological type of EC with a high mortality rate and poor prognosis, is characterized by strong invasiveness, high postoperative recurrence rate, and multifocal recurrence, and is mostly located outside the pelvic cavity [2][3][4]. Trastuzumab (T), a monoclonal antibody against the human epidermal growth factor receptor (HER2/neu), showed clinical benefits for breast cancer and gastric cancer in several randomized controlled trials (RCTs) [5].…”

Section: Introductionmentioning

confidence: 99%

Effect of the combination of trastuzumab, paclitaxel and carboplatin in the treatment of uterine serous carcinoma: A systematic review and meta-analysis

Yu,

Ma,

Wang

2023

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To systematically review the efficacy of paclitaxel-carboplatin versus trastuzumab in combination with paclitaxel/carboplatin for the treatment of uterine serous carcinoma (USC) with high Her2/neu expression, in order to obtain an evidence-based reference for clinical treatment.Methods: Publications were obtained from China Knowledge Network (CNKI), VIP database (VIP), Wanfang database, PubMed, Embase, Cochrane Library, and Web of Science. The retrieval period was from the establishment of database to May 2022, and the efficacy of paclitaxel-carboplatin combination with trastuzumab (study group) versus paclitaxel-carboplatin (control group) for the treatment of Her2/neu high-expressing USC was collected. Two reviewers independently screened, extracted data, and evaluated the quality of evidence of included studies. RevMan 5.3 statistical software was used for meta-analysis. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events.Results: Meta-analysis showed that the study group had significantly longer OS than control group (p = 0.004), and PFS of study group was significantly longer than that of control group (p < 0.0001). In terms of ORR, there was no difference between the two groups (p = 0.42). However, in terms of total and high-risk adverse events, the number of patients with adverse events in study group was higher than in control group (p = 0.05), (p = 0.0001).Conclusion: Paclitaxel-carboplatin combination with trastuzumab significantly prolongs OS and PFS in USC patients with high Her2/neu expression, but it may increase the incidence of adverse events.

show abstract

Discovering common pathogenetic processes between polycystic ovary syndrome and uterine corpus endometrial carcinoma by bioinformatics and experimental approach

Wang,

Diao,

Richard

et al. 2024

Arabian Journal of Chemistry

View full text Add to dashboard Cite

Identification of core genes shared by endometrial cancer and ovarian cancer using an integrated approach

Cited by 6 publications

References 0 publications

TMCO1 regulates cell proliferation, metastasis and EMT signaling through CALR, promoting ovarian cancer progression and cisplatin resistance

TMCO1 regulates cell proliferation, metastasis and EMT signaling through CALR, promoting ovarian cancer progression and cisplatin resistance

Effect of the combination of trastuzumab, paclitaxel and carboplatin in the treatment of uterine serous carcinoma: A systematic review and meta-analysis

Discovering common pathogenetic processes between polycystic ovary syndrome and uterine corpus endometrial carcinoma by bioinformatics and experimental approach

Contact Info

Product

Resources

About